抑郁症的增效治疗（二）——齐拉西酮对伴有精神病性症状抑郁症的治疗作用

目的：探讨齐拉西酮治疗伴有精神病性症状抑郁症的临床疗效。方法：60例伴有精神病性症状的抑郁症患者随机分为合用组28例（齐拉西酮联合帕罗西汀治疗）和单用组32例（单用帕罗西汀治疗）,疗程6周。采用汉密尔顿抑郁量表（HAMD）、简明精神病评定量表（BPRS）、临床疗效总评量表（CGI）和治疗中出现的症状量表（TESS）评定临床疗效和不良反应。结果：治疗后两组HAMD、BPRS及CGI评分均较治疗前明显下降（P〈0.05或P〈0.01）;两组比较,以合用组降低更为显著（P〈0.05或P〈0.01）。合用组TESS评分（2.11±1.20）分和单用组TESS评分（1.9±0.16）分差异无统计学意义（P〉0.05）。结论：齐拉西酮联合帕罗西汀治疗伴有精神病性症状的抑郁症临床疗效优于单用帕罗西汀。

Study of efficacy of ziprasidone combined with paroxetine in the treatment of depression with psychotic symptoms

Objective： To explore the clinical efficacy of ziprasidone combined with paroxetine in the treatment of depression with psychotic symptoms. Method：60 patients of major depression with psychotic symptoms were randomly assigned into the study group and the control one, treated respectively by paroxetine with and without ziprasidone for 6 weeks. The clinical efficacy was evaluated with Hamilton depression scale （HAMD） ,brief psychiatric rating scale（BPRS） and clinical global impression（CGI） , and the side effects was evaluated with treatment emergent symptom scale（TESS） before and after treatments. Results：Scores reduced of the scales of HAMD, BPRS and CGI in the study group were higher than which in the control one, and the incidence of side effects in the two groups had no statistcal difference. Conclusion：Ziprasidone combined with paroxetine is better than paroxetine for treating major depression with psychotic symptoms.